Bachem Holding AG (SWX: BANB)
Health Care · Life Sciences Tools & Services · CH
CHF80.90
+1.06% today · +37.7% 1Y
Bachem Holding AG (SWX: BANB) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $7.22B and employs 2,725 people.
Over the last twelve months the share price has gained 37.7%, trading between 48.52 and 84.10.
Tweenvest scores Bachem Holding AG across four factors: quality 81/100, value 51/100, growth 75/100, dividend 76/100. Its strongest factor is quality.
BANB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $7.22B
- Revenue (TTM)
- $876.89M
- P/E
- 40.35
- EPS
- 1.98
- Dividend yield
- 1.16%
- Beta (5Y)
- 0.79
- 52-week high
- CHF84.10
- 52-week low
- CHF48.52
- Avg volume (3M)
- —
- Shares outstanding
- 74.94M
- Employees
- 2,725
- Next earnings
- —
About Bachem Holding AG
Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
- ISIN
- CH1176493729
- Founded
- 1971
- Listed since
- Jul 17, 1998
- Exchange
- SIX Swiss Exchange
- Currency
- CHF
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Repligen CorporationNasdaqGS: RGEN | $9.81B | $171.26 | -1.51% |
| Bio-Rad Laboratories, Inc.NYSE: BIO | $9.78B | $361.49 | -1.28% |
| Qiagen N.V.NYSE: QGEN | $9.38B | $45.23 | -0.33% |
| Bruker CorporationNasdaqGS: BRKR | $8.96B | $56.97 | -3.18% |
| Hangzhou Tigermed Consulting Co., LtdSZSE: 300347 | $6.56B | CN¥55.18 | -5.51% |
| Joinn Laboratories(China)Co.,Ltd.SHSE: 603127 | $5.35B | CN¥52.60 | +6.69% |
| Stevanato Group S.p.A.NYSE: STVN | $5.30B | $19.38 | -0.10% |
| Sotera Health CompanyNasdaqGS: SHC | $5.15B | $18.12 | +0.33% |
Figures last refreshed Oct 11, 2026.